FDA Under Trump and the Future of Psychedelics
Briefly

from Psychology Today1 month ago
Kennedy's assertion highlights a growing discourse around the FDA's regulatory approach and its impact on mental health treatments, particularly due to the unmet need for effective therapies.
Psychology Todayhttps://www.psychologytoday.com/us/blog/psychedelics-to-the-rescue/202412/fda-under-trump-and-the-future-of-psychedelics
The rejection of MDMA-assisted therapy for PTSD emphasizes ongoing challenges in approving psychedelics, despite increasing political support and clinical research efforts in mental health care.
Psychology Todayhttps://www.psychologytoday.com/us/blog/psychedelics-to-the-rescue/202412/fda-under-trump-and-the-future-of-psychedelics
FDA decisions on psychedelics often reflect political influences over purely scientific data, which poses obstacles to accessing innovative mental health treatments.
Psychology Todayhttps://www.psychologytoday.com/us/blog/psychedelics-to-the-rescue/202412/fda-under-trump-and-the-future-of-psychedelics
Expanding the use of psychedelics in mental health care necessitates careful attention to training, ethics, and safety to ensure effective and responsible implementation.
Psychology Todayhttps://www.psychologytoday.com/us/blog/psychedelics-to-the-rescue/202412/fda-under-trump-and-the-future-of-psychedelics
Read at Psychology Today
#psychedelics #fda #mental-health #regulation #trump-administration
[
|
]